The FDA approved omalizumab-igec (Omlyclo) as the first biosimilar for omalizumab (Xolair) and the first for any respiratory ...

Among trial finishers, omalizumab and oral immunotherapy offered similar protection against food allergies, and some people ...

Omalizumab works by binding to the allergy-causing antibody called immunoglobulin E in the blood and preventing it from arming key immune cells responsible for allergic reactions.

Clinical trial shows omalizumab (Xolair) treats multiple severe food allergies more effectively than oral immunotherapy, with ...

Thirty-six percent of patients treated with omalizumab were able to tolerate 2000mg of peanut protein and 2 other food allergens without experiencing an allergic reaction compared with 19% of OIT ...

Celltrion today announced the U.S. Food and Drug Administration (FDA) approved OMLYCLO® (omalizumab-igec) as the first and ...

A clinical trial has found that the medication omalizumab, marketed as Xolair, treated multi-food allergy more effectively than oral immunotherapy (OIT) in people with allergic reactions to very ...

Patients received omalizumab with placebo oral immunotherapy or vice versa. 88% of the omalizumab group and 51% of the OIT group completed treatment. There were no serious adverse events with ...

Omalizumab, marketed as Xolair, proved more effective than oral immunotherapy (OIT) in treating multi-food allergies in individuals with severe sensitivities to common food allergens.

JERSEY CITY, N.J., March 9, 2025 /PRNewswire/ -- Celltrion today announced the U.S. Food and Drug Administration (FDA) approved OMLYCLO® (omalizumab-igec) as the first and only biosimilar ...